Institution
University of Ioannina
Education•Ioannina, Greece•
About: University of Ioannina is a education organization based out in Ioannina, Greece. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 7654 authors who have published 20594 publications receiving 671560 citations. The organization is also known as: Panepistimio Ioanninon.
Papers published on a yearly basis
Papers
More filters
••
Vardan Khachatryan1, Albert M. Sirunyan1, Armen Tumasyan1, Wolfgang Adam +2121 more•Institutions (139)
TL;DR: In this paper, searches for the direct electroweak production of supersymmetric charginos, neutralinos, and sleptons in a variety of signatures with leptons and W, Z, and Higgs bosons are presented.
Abstract: Searches for the direct electroweak production of supersymmetric charginos, neutralinos, and sleptons in a variety of signatures with leptons and W, Z, and Higgs bosons are presented. Results are based on a sample of proton-proton collision data collected at center-of-mass energy sqrt(s) = 8 TeV with the CMS detector in 2012, corresponding to an integrated luminosity of 19.5 inverse femtobarns. The observed event rates are in agreement with expectations from the standard model. These results probe charginos and neutralinos with masses up to 720 GeV, and sleptons up to 260 GeV, depending on the model details.
346 citations
••
S. Chatrchyan1, Vardan Khachatryan1, Albert M. Sirunyan1, Armen Tumasyan1 +2280 more•Institutions (177)
TL;DR: In this paper, a search for a standard model Higgs boson decaying into a pair of tau leptons is performed using events recorded by the CMS experiment at the LHC in 2011 and 2012.
Abstract: A search for a standard model Higgs boson decaying into a pair of tau leptons is performed using events recorded by the CMS experiment at the LHC in 2011 and 2012. The dataset corresponds to an integrated luminosity of 4.9 inverse femtobarns at a centre-of-mass energy of 7 TeV and 19.7 inverse femtobarns at 8 TeV. Each tau lepton decays hadronically or leptonically to an electron or a muon, leading to six different final states for the tau-lepton pair, all considered in this analysis. An excess of events is observed over the expected background contributions, with a local significance larger than 3 standard deviations for m[H] values between 115 and 130 GeV. The best fit of the observed H to tau tau signal cross section for m[H] = 125 GeV is 0.78 +- 0.27 times the standard model expectation. These observations constitute evidence for the 125 GeV Higgs boson decaying to a pair of tau leptons.
345 citations
••
National and Kapodistrian University of Athens1, Athens Regional Medical Center2, Aristotle University of Thessaloniki3, Democritus University of Thrace4, University of Ioannina5, Alexandra Hospital6, University of Patras7, Instituto Politécnico Nacional8, Yale University9, Icahn School of Medicine at Mount Sinai10
TL;DR: A role for colchicine in the treatment of patients with coronavirus disease 2019 is suggested, with results suggesting a smaller increase in dimerized plasma fragment D compared with patients in the control group.
Abstract: Importance Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic Low-dose colchicine combines anti-inflammatory action with a favorable safety profile Objective To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19) Design, Setting, and Participants In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment The study took place in 16 tertiary hospitals in Greece Intervention Colchicine administration (15-mg loading dose followed by 05 mg after 60 min and maintenance doses of 05 mg twice daily) with standard medical treatment for as long as 3 weeks Main Outcomes and Measures Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death Secondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events The primary efficacy analysis was performed on an intention-to-treat basis Results A total of 105 patients were evaluated (61 [581%] men; median [interquartile range] age, 64 [54-76] years) with 50 (476%) randomized to the control group and 55 (524%) to the colchicine group Median (interquartile range) peak high-sensitivity cardiac troponin values were 00112 (00043-00093) ng/mL in the control group and 0008 (0004-00135) ng/mL in the colchicine group (P = 34) Median (interquartile range) maximum C-reactive protein levels were 45 (14-89) mg/dL vs 31 (08-98) mg/dL (P = 73), respectively The clinical primary end point rate was 140% in the control group (7 of 50 patients) and 18% in the colchicine group (1 of 55 patients) (odds ratio, 011; 95% CI, 001-096;P = 02) Mean (SD) event-free survival time was 186 (083) days the in the control group vs 207 (031) in the colchicine group (log rankP = 03) Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [455%] vs 9 patients [180%];P = 003) Conclusions and Relevance In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels These findings should be interpreted with caution Trial Registration ClinicalTrialsgov Identifier:NCT04326790
345 citations
••
University of Ottawa1, University of Ioannina2, Tufts University3, Cochrane Collaboration4, University of Bern5, Centers for Disease Control and Prevention6, PLOS7, University of Bristol8, University of Texas MD Anderson Cancer Center9, Robarts Research Institute10, University of Western Ontario11, Erasmus University Rotterdam12, Cancer Care Ontario13, McGill University14, Harvard University15
TL;DR: The STREGA recommendations do not prescribe or dictate how a genetic association study should be designed but seek to enhance the transparency of its reporting, regardless of choices made during design, conduct, or analysis.
Abstract: Making sense of rapidly evolving evidence on genetic associations is crucial to making genuine advances in human genomics and the eventual integration of this information in the practice of medicine and public health. Assessment of the strengths and weaknesses of this evidence, and hence the ability to synthesize it, has been limited by inadequate reporting of results. The STrengthening the REporting of Genetic Association studies (STREGA) initiative builds on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement and provides additions to 12 of the 22 items on the STROBE checklist. The additions concern population stratification, genotyping errors, modeling haplotype variation, Hardy-Weinberg equilibrium, replication, selection of participants, rationale for choice of genes and variants, treatment effects in studying quantitative traits, statistical methods, relatedness, reporting of descriptive and outcome data, and the volume of data issues that are important to consider in genetic association studies. The STREGA recommendations do not prescribe or dictate how a genetic association study should be designed but seek to enhance the transparency of its reporting, regardless of choices made during design, conduct, or analysis.
344 citations
••
TL;DR: In this paper, a two-parameter distribution with decreasing failure rate is introduced and various properties are discussed and the estimation of parameters is studied by the method of maximum likelihood, which is attained by the EM algorithm and expressions for their asymptotic variances and covariances are obtained.
344 citations
Authors
Showing all 7724 results
Name | H-index | Papers | Citations |
---|---|---|---|
John P. A. Ioannidis | 185 | 1311 | 193612 |
Kay-Tee Khaw | 174 | 1389 | 138782 |
Elio Riboli | 158 | 1136 | 110499 |
Mercouri G. Kanatzidis | 152 | 1854 | 113022 |
Dimitrios Trichopoulos | 135 | 818 | 84992 |
Gyorgy Vesztergombi | 133 | 1444 | 94821 |
Niki Saoulidou | 132 | 1065 | 81154 |
Apostolos Panagiotou | 132 | 1370 | 88647 |
Ioannis Evangelou | 131 | 1225 | 82178 |
Ioannis Papadopoulos | 129 | 1201 | 85576 |
Nikolaos Manthos | 129 | 1256 | 81865 |
Panagiotis Kokkas | 128 | 1234 | 81051 |
Costas Foudas | 128 | 1112 | 83048 |
Zoltan Szillasi | 128 | 1214 | 84392 |
Matthias Schröder | 126 | 1421 | 82990 |